Drug profile · INN
eliglustat tartrate
CERDELGA
eliglustat tartrate (CERDELGA) is a ceramide glucosyltransferase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — eliglustat tartrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 1
- Programs
- 0
- Data quality
- 0.89
Quick answer
eliglustat tartrate (CERDELGA) is a ceramide glucosyltransferase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Ceramide glucosyltransferase inhibitor
Primary target: Ceramide glucosyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| PMDA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is eliglustat tartrate?
eliglustat tartrate (CERDELGA) is a ceramide glucosyltransferase inhibitor. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for eliglustat tartrate?
CERDELGA is a marketed brand name for eliglustat tartrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of eliglustat tartrate?
eliglustat tartrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.